NIKKEI 225
39,126.74 +88.58 (+0.23%) HANG SENG
18,027.26 -339.69 (-1.85%) CRUDE OIL
77.67 -0.07 (-0.09%) GOLD FUTURES
2,318.90 -8.10 (-0.35%) DOW
38,868.04 +69.05 (+0.18%) Bitcoin GBP
53,505.22 -1,273.51 (-2.32%)
GILD Nov 2024 55.000 call
| Previous close | 10.65 |
| Open | 10.10 |
| Bid | 10.90 |
| Ask | 12.50 |
| Strike | 55.00 |
| Expiry date | 2024-11-15 |
| Day's range | 10.10 - 10.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.75k |
ZacksGilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
ZacksInvestors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
